Spironolactone and Canrenone Inhibit UGT2B7-Catalyzed Human Liver and Kidney Microsomal Aldosterone 18{Beta}-Glucuronidation: A Potential Drug Interaction

dc.contributor.author Knights, Kathleen Mary
dc.contributor.author Bowalgaha Ralalage, Kushari Wathsala
dc.contributor.author Miners, John Oliver
dc.date.accessioned 2014-09-30T06:11:51Z
dc.date.available 2014-09-30T06:11:51Z
dc.date.issued 2010 en_US
dc.identifier.citation Knights, K.M., Bowalgaha Ralalage, K.W. and Miners, J.O. (2010). Spironolactone and Canrenone Inhibit UGT2B7-Catalyzed Human Liver and Kidney Microsomal Aldosterone 18{Beta}-Glucuronidation: A Potential Drug Interaction. Drug Metabolism and Disposition, 38(7) pp. 1011-1014. en
dc.identifier.doi https://doi.org/10.1124/dmd.110.032870 en
dc.identifier.issn 0090-9556 en_US
dc.identifier.rmid 2006018607 en_US
dc.identifier.uri http://hdl.handle.net/2328/33046
dc.subject.forgroup 1115 Pharmacology and Pharmaceutical Sciences en_US
dc.title Spironolactone and Canrenone Inhibit UGT2B7-Catalyzed Human Liver and Kidney Microsomal Aldosterone 18{Beta}-Glucuronidation: A Potential Drug Interaction en_US
dc.type Article en_US
Files